Clearside Biomedical/$CLSD
About Clearside Biomedical
Ticker
Industry
Employees
CLSD Metrics
$72M
-
-$0.46
2.33
-
Price and volume
Market cap
$72M
Beta
2.33
52-week high
$2.12
52-week low
$0.80
Average daily volume
192K
Financial strength
Current ratio
4.49
Quick ratio
4.359
Long term debt to equity
-142.574
Total debt to equity
-143.646
Interest coverage (TTM)
-2.60%
Management effectiveness
Return on assets (TTM)
-48.46%
Return on equity (TTM)
133.83%
Valuation
Price to revenue (TTM)
8.687
Price to book
-2.04
Price to tangible book (TTM)
-2.04
Price to free cash flow (TTM)
-3.414
Growth
Revenue change (TTM)
248.39%
Earnings per share change (TTM)
-25.34%
3-year revenue growth (CAGR)
25.48%
3-year earnings per share growth (CAGR)
0.05%
What the Analysts think about CLSD
Analyst Ratings
CLSD Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
CLSD Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
CLSD News

Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
What’s the current market cap for Clearside Biomedical stock?
What is the P/E ratio for Clearside Biomedical stock?
Does Clearside Biomedical stock pay dividends?
No, Clearside Biomedical (CLSD) stock does not pay dividends to its shareholders as of February 24, 2025.
When is the next Clearside Biomedical dividend payment date?
Clearside Biomedical (CLSD) stock does not pay dividends to its shareholders.
What is the beta indicator for Clearside Biomedical?
Clearside Biomedical (CLSD) has a beta rating of 2.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.